60 DEGREES PHARMACEUTICALS LLC (SXTP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.94-3.75%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — reduce EPS losses from -$3.45 in FY26 toward breakeven: metric not reported.
60 Degrees Pharmaceuticals aims to grow revenue by about 37% next year to $900 million. The company is developing therapies for infectious diseases and has a new director on board. Its stock trades cheaply at a price-to-sales ratio of 2.89, well below peers. If clinical trials succeed, it could improve earnings and cash flow.
The company is loss-making with negative free cash flow yield of -2.83%. Earnings per share are expected to remain negative at -$3.45 in 2026 and -$3.58 in 2027. Recent litigation and Nasdaq delisting notices raise risks. Revenue growth may slow or fail to materialize.
The market prices in about 37% revenue growth next year but also reflects high risk given the 24% drawdown and negative earnings. Our fair value estimate near $8 aligns with consensus but the stock trades 79% below consensus price, indicating skepticism. We see risk in earnings and cash flow.
Breaks if: EPS loss worsens beyond -$3.45 in FY26
Breaks if: litigation results in material financial loss or delays
Breaks if: revenue falls below $900 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds uncertainty to its future performance.
The market seems to have priced in a low level of fragility, suggesting that expectations are somewhat justified. SXTP is viewed as cheap compared to its peers, but there is an expectations gap indicating that the market anticipates challenges ahead.
Fundamentals are likely to remain under pressure in the near term, given the high probability of an earnings miss and ongoing operating losses. Recent financial performance has been neutral, but revenue has declined significantly, indicating limited progress toward profitability.
The long-term thesis hinges on management's ability to achieve profitability by 2028 and successfully submit a New Drug Application for tafenoquine. Additionally, the performance of sector bellwethers and the overall economic environment will significantly influence SXTP's trajectory.
In the next 1 to 3 years, SXTP faces significant challenges that could impact its growth prospects. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.